Klebsiella oxytoca (K. oxytoca) is a Gram-negative microbe generally associated with community and hospitalacquired infections. Due to its clinical significance, we evaluated the effect of biofield treatment on phenotype and biotype characteristics of K. oxytoca (ATCC 43165). The study was performed into three groups i.e. C (control), T1 (treatment, revived); and T2 (treatment, lyophilized). Subsequently, groups T1 and T2 were received biofield treatment and control group was remained as untreated. The antimicrobial sensitivity results showed 3.33% and 6.67% alteration in antimicrobials susceptibility in group T1 cells on day 5 and 10, respectively, and 3.33% alteration in antimicrobials susceptibility was observed in group T2 cells on day 10 as compared to control. The sensitivity patterns of cefazolin were changed from resistant (R) to intermediate (I) on day 5, and resistance (R) to susceptible (S) on day 10, in T1 cells of K. oxytoca. The MIC value of cefazolin was decreased by 2-fold in group T1 on day 10 as compared to control. The biofield treated K. oxytoca exhibited the changes in biochemical reactions about 3.03% and 15.15% of total tested biochemicals in group T1 cells on day 5 and 10, respectively as compared to control. The biotype number of K. oxytoca was altered in biofield treated group and organism identified as Raoultella ornithinolytica in T1 on day 10 as compared to control, which is the prominent finding of this study. These changes were found in treated bacteria that might be due to some alteration happened in metabolic/enzymatic pathway and/ or at genetic level of K. oxytoca. Based on these data, it is speculated that biofiled treatment could be an alternative approach that can improve the effectiveness of the existing antimicrobials against the resistant pathogens.

No abstract

Study background: Nowadays, hepatitis is a major challenge for clinical research, regulatory bodies, and clinicians who are trying to assess the more effectiveness of antiviral therapy against patients. Viral load count is the amount of particular viral DNA or RNA in a blood samples. It is one of the surrogate biomarker of hepatitis. High viral load indicates that the immune system is failed to fight against viruses. The aim of this study was to evaluate the impact of biofield modality on hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of viral load as surrogate marker. Method:The viral load assay was performed on stock human plasma samples of HBV and HCV before and after 7 days of biofield treatment using Roche COBAS® AMPLICOR analyzer according to manufacturer's instructions. Viremia (viral DNA for HBV, RNA for HCV) was considered as surrogate marker for assessment of the impact of Mr. Trivedi's biofield treatment. Result:The viral load of HBV DNA in infected plasma samples showed a significant alteration in the biofield treated group as compared to control. Additionally, viral load count of HCV RNA in infected plasma samples was significantly reduced by 67% in the biofield treated group as compared to control. As the biofield treatment has significantly reduced HCV RNA, it could be beneficial for particularly HCV infected populations. Conclusion:Altogether, data suggest that biofield treatment has significantly alteration in HBV and reduced the viral load count in HCV infected plasma samples and could be a suitable alternative treatment strategy for hepatitis patients in near future.

The aim was to evaluate the impact of biofield treatment modality on mycobacterial strains in relation to antimycobacterials susceptibility. Mycobacterial sensitivity was analysed using 12 B BACTEC vials on the BACTEC 460 TB machine in 39 lab isolates (sputum samples) from stored stock cultures. Two American Type Culture Collection (ATCC) strains were also used to assess the minimum inhibitory concentration (MIC) of antimicrobials (Mycobacterium smegmatis 14468 and Mycobacterium tuberculosis 25177). Rifampicin, ethambutol and streptomycin in treated samples showed increased susceptibility as 3.33%, 3.33% and 400.6%, respectively, as compared to control in extensive drug resistance (XDR) strains. Pyrazinamide showed 300% susceptibility as compared to control in multidrug resistance (MDR) strains. Isoniazide did not show any improvement of susceptibility pattern against treated either in XDR or MDR strains of Mycobacterium as compared to control. Besides susceptibility, the resistance pattern of treated group was reduced in case of isoniazide (26.7%), rifampicin (27.6%), pyrazinamide (31.4%), ethambutol (33.43%) and streptomycin (41.3%) as compared to the untreated group of XDR strains. The MIC values of few antimicrobials were also altered in the treated group of Mycobacterium smegmatis. There was a significant reduction observed in MIC values of linezolid (8.0 to 2.0 µg/ml) and tobramycin (2.0 to 1.0 µg/ml); however, very slight changes occurred in the remaining antimicrobials of treated samples. There was no change of MIC values in the strain of Mycobacterium tuberculosis after biofield treatment. Biofield treatment effect on Mycobacterium against anti-tubercular drugs might be due to altered ligand-receptor/protein interactions at either enzymatic and/or genetic level with respect to anti-mycobacterium susceptibility and MIC values of antimicrobials.

Burkholderia cepacia (B. cepacia) is an opportunistic, Gram negative pathogen which causes infection mainly in immunocompromised population and associated with high rate of morbidity and mortality in cystic fibrosis patients. Aim of the present study was to analyze the impact of biofield treatment on multidrug resistant B. cepacia. Clinical sample of B. cepacia was divided into two groups i.e. control and biofield treated. The analysis was done after 10 days of treatment and compared with control group. Control and treated group were analyzed for susceptibility pattern, MIC value, biochemical studies and biotype number using MicroScan Walk-Away® system. Sensitivity assay results showed a change in pattern from resistant to intermediate in aztreonam, intermediate to resistant in ceftazidime, ciprofloxacin, imipenem, and levofloxacin while sensitive to resistant in meropenem and piperacillin/ tazobactam. The biofield treatment showed an alteration in MIC values of aztreonam, ceftazidime, chloramphenicol, ciprofloxacin, imipenem, levofloxacin, meropenem, piperacillin/tazobactam and tetracycline. Biochemical reactions of treated group showed negative reaction in colistin, lysine, and ornithine while positive reactions to acetamide, arginine, and malonate as compared to control. Overall results showed an alteration of 38.9% in susceptibility pattern, 30% in MIC values of tested antimicrobials and 18.2% change in biochemical reaction after biofield treatment. A significant change in biotype number (02063736) was reported with green pigment as special characteristics after biofield treatment as compared to control (05041776) group with yellow pigment. In treated group, a new species was identified as Pseudomonas aeruginosa, as compared to control. Study findings suggest that biofield treatment has a significant effect on the phenotypic character and biotype number of multidrug resistant strain of B. cepacia.

The stability of any pharmaceutical compound is most desired quality that determines its shelf life and effectiveness. The stability can be correlated to structural and bonding properties of compound and any variation arise in these properties can be easily determined by spectroscopic analysis. The present study was aimed to evaluate the impact of biofield treatment on these properties of four pharmaceutical compounds such as urea, thiourea, sodium carbonate, and magnesium sulphate, using spectroscopic analysis. Each compound was divided into two groups, referred as control and treatment. The control groups remained as untreated and treatment group of each compound received Mr. Trivedi's biofield treatment. Control and treated samples of each compound were characterized using FourierTransform Infrared (FT-IR) and Ultraviolet-Visible (UV-Vis) spectroscopy. FT-IR spectra of biofield treated urea showed the shifting of C=O stretching peak towards lower frequency (1684→1669 cm -1 ) and N-H stretching peak towards higher frequency (3428→3435 cm -1 ) with respect to control. A shift in frequency of C-N-H bending peak was also observed in treated sample as compared to control i.e. (1624→1647 cm -1 ). FT-IR spectra of thiourea showed upstream shifting of NH 2 stretching peak (3363→3387 cm -1 ) as compared to control, which may be due to decrease in N-H bond length. Also, the change in frequency of N-C-S bending peak (621→660 cm -1 ) was observed in treated thiourea that could be due to some changes in bond angle after biofield treatment. Similarly, treated sample of sodium carbonate showed decrease in frequency of C-O bending peak (701→690 cm -1 ) and magnesium sulphate showed increase in frequency of S-O bending peak (621→647 cm -1 ) as compared to control, which indicated that bond angle might be altered after biofield treatment on respective samples. UV-Vis spectra of biofield treated urea showed shift in lambda max (λ max ) towards higher wavelength (201→220 nm) as compared to control sample, whereas other compounds i.e. thiourea, sodium carbonate, and magnesium sulphate showed the similar λ max to their respective control. These findings conclude that biofield treatment has significant impact on spectral properties of tested pharmaceutical compounds which might be due to some changes happening at atomic level of compounds, and leading to affect the bonding and structural properties of compounds.

Streptococcus agalactiae group B (S. agalactiae gr. B) is widespread in nature mainly causes bacterial septicemia and neonatal meningitis. The current study was attempted to investigate the effect of biofield treatment on S. agalactiae gr. B with respect of antimicrobial sensitivity, biochemical reactions and bio typing. S. agalactiae gr. B strain was used in this experiment bearing the American Type Culture Collection (ATCC 12386) number and stored according to the recommended storage protocol. The revived and lyophilized state of ATCC strains of S. agalactiae gr. B were selected for the study. Gr. I was considered as control. Both revived (Group; Gr. II) and lyophilized (Gr. III) strains of S. agalactiae gr. B were subjected to Mr. Trivedi's biofield treatment. Gr. II was assessed on day 5 and day 10 while Gr. III on day 10 with respect to the control (Gr. I) using MicroScan Walk-Away ® system. Although biofield treatment did not show any change with respect to susceptibility pattern. However the minimum inhibitory concentration of S. agalactiae gr. B showed significant (70.37%) alteration, out of twenty-seven tested antimicrobials, among which in Gr. II i.e. 62.96% on day 5 and 66.67% on day 10 while no alteration was found in lyophilized group (Gr. III) as compared to the control. Moreover, the improvement of MIC value of norfloxacin was observed by two-fold (8 to ≤4 µg/mL) in Gr. II on day 10 after biofield energy treatment as compared to the control. It was observed that overall 48.28% biochemical reactions, out of twenty-nine were altered in Gr. II with respect to the control. Moreover, biotype numbers were changed in Gr. II on day 5 (777777615) and on day 10 (757677405) as compared to the control (237147047). The results suggest that biofield treatment has significant impact on S. agalactiae gr. B in revived treated cells (Gr. II) with respect to MIC values, biochemical reactions pattern and biotype number.

Global emergence of Acinetobacter baumannii (A. baumannii) displays a mechanism of resistance to all existing antimicrobials. Objective of this study was to investigate the effect of biofield treatment on antimicrobial sensitivity pattern, minimum inhibitory concentration (MIC), biochemical reactions and biotype number of A. baumannii. A. baumannii cells were procured from MicroBioLogics in sealed packs bearing the American Type Culture Collection (ATCC 19606) number and stored according to the recommended storage protocols until needed for experiments. Two sets of ATCC samples were taken in this experiment and denoted as A and B. ATCC-A sample was revived and divided into two parts i.e. Gr.I (control) and Gr.II (revived) analyzed on day 5 and 10, respectively; likewise, ATCC-B was labeled as Gr.III (lyophilized) and was assessed on day 10. Gr.II and III were treated with Mr. Trivedi's biofield and were analyzed for its antimicrobial sensitivity, MIC value, biochemical reactions and biotype number with respect to control. Experimental results showed the impact of biofield treatment directly onto the revived and lyophilized form of A. baumannii and found alteration both in qualitative and quantitative aspect as compared with untreated groups. These results showed altered sensitivity pattern of antimicrobials in biofield treated group as compared to control. Apart from altered MIC values, changes were also observed in biotype number of revived treated group as compared to control. These findings suggest that biofield treatment can prevent the emergence of absolute resistance of existing antimicrobials to A. baumannii.